roxadustat + retinoic acid

Roxadustat + retinoic acid is a combination of two small molecule drugs, each with distinct but potentially complementary mechanisms related to erythropoiesis and cellular differentiation. Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor that increases endogenous erythropoietin production, stimulates hemoglobin synthesis, and improves iron metabolism. It is primarily used for the treatment of anemia associated with chronic kidney disease[1][5][7]. Retinoic acid refers to the active metabolite forms of vitamin A (such as all-trans-retinoic acid), which act as agonists at nuclear retinoic acid receptors (RARs) and regulate gene expression involved in cell growth, differentiation, and hematopoiesis[6]. Preclinical studies suggest that retinoic acid can regulate erythropoietin production in EPO-producing cells[2]. There are no approved pharmaceutical products or widely recognized clinical trials specifically combining roxadustat with retinoic acid; this combination should be considered experimental.